Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Low molecular weight heparin--1998 status].

G A Marbet1

  • 1Hämostaselabor DZL, Kantonsspital Basel.

Praxis
|July 20, 1999
PubMed
Summary

Low molecular weight heparins (LMWHs) are proving effective for various prophylactic and therapeutic uses, rivaling unfractionated heparin. Their improved properties make LMWHs a preferred choice for treating thromboembolism and related conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prosthetic heart valves and rare hypersensitivity to vitamin K antagonists resulting from factor IX mutation: how to manage anticoagulation?

Haemophilia : the official journal of the World Federation of Hemophilia·2009
Same author

Unexpected bleeding following eyelid tumor resection leading to the rare diagnosis of acquired haemophilia.

Klinische Monatsblatter fur Augenheilkunde·2008
Same author

Quantification of coagulation factors and inhibitors. Still a special task.

Hamostaseologie·2006
Same author

[Heparins].

Therapeutische Umschau. Revue therapeutique·2003
Same author

[Factor XIII in man: a review].

Hamostaseologie·2002
Same author

Influence of the genetic background on platelet function, microparticle and thrombin generation in the common laboratory mouse.

Platelets·2002

Area of Science:

  • Pharmacology
  • Cardiology
  • Hematology

Background:

  • Classical unfractionated heparin (UFH) has been the standard anticoagulant.
  • Advances in anticoagulant therapy have led to the development of low molecular weight heparins (LMWHs).

Purpose of the Study:

  • To compare the efficacy and pharmacokinetic properties of LMWHs with UFH.
  • To evaluate LMWHs for various prophylactic and therapeutic indications.

Main Methods:

  • Extensive review of existing literature.
  • Analysis of recent comparative clinical studies.

Main Results:

  • LMWHs demonstrate successful coverage of prophylactic and therapeutic indications of UFH.
  • LMWHs exhibit similar antithrombotic mechanisms to UFH but possess superior pharmacokinetic properties.
  • LMWHs are the preferred choice for acute venous thromboembolism prophylaxis and treatment, hemodialysis clot prevention, and managing unstable angina pectoris.

Conclusions:

  • LMWHs are emerging as a superior alternative to UFH, often termed "better heparin".
  • Current evidence supports LMWHs as a first-line treatment for several thrombotic conditions.
  • Further research may extend the use of LMWHs to other arterial circulation applications.

Related Experiment Videos